<DOC>
	<DOCNO>NCT02226029</DOCNO>
	<brief_summary>Quantitative MR method validate non-invasive imaging GI processing lipid emulsion 18 ( 12+6 ) healthy subject . Validation perform randomize single blind two-armed crossover trial two isovolumetric isocaloric lipid emulsion different microstructural property . Hypotheses sudy 1. fat fraction lipid emulsion GI tract monitor quantitative MR method 13C-sodium octanoate 2 . 13C-sodium acetate lipid emulsion exhibit different excretion profile due oppose bind affinity water fat .</brief_summary>
	<brief_title>Quantitative MR Methods Lipid Emulsions</brief_title>
	<detailed_description>Participants give two lipid emulsion different physicochemical composition randomize order two separate visit . A nasogastric tube apply intragastric lipid emulsion infusion control effect inter-individual tolerance texture taste lipid emulsion . Standard MR measurement perform regularly assess intragastric fat content relate fat content empty period 3 hour . At different pre-defined time point gastric process empty emulsion , five sample gastric content ( 5x2 ml ) aspirate via nasogastric tube determine local intragastric fat content density measurement . The measured fat fraction aspirate sample validate non-invasive quantitative MR measurement . Each participant also undergo either 13C-sodium acetate 13C-sodium octanoate breath test two visit . Breath test carry throughout MR imagine period 2 hour post imaging . A subset participant undergo breath test procedure without use MR gastric content sample . 2 isovolumetric ( 200 ml ) isocaloric ( 200 kcal ) lipid emulsion different acid shear stability . 13C-markers mixed emulsion . - Lipid emulsion 1 : acid stable , particle size 0.6 µm - Lipid emulsion 2 : acid unstable , redispersible mechanical process antral contraction passage pylorus , particle size 0.6 µm Power calculation base in-vitro pilot experiment , determine variation detection fat fraction lipid emulsion 1.5 % . With 12 enrolled subject , detectable difference fat fraction significance level 0.05 defined power 0.9 2 % . In 18 enrolled subject ( 12+6 ) separate two group 9 , detectable difference 13CO2 recovery significance level 0.05 defined power 0.9 0.15 Percent Dose Recovered per hr ( PDR/hr ) . This study conduct compliance protocol , current version Declaration Helsinki , ICH-GCP ISO EN 14155 ( far applicable ) well national legal regulatory requirement .</detailed_description>
	<criteria>Men woman age 18 50 BMI 1825 kg/m² Written inform consent History GI , cardiorespiratory ( include arterial hypertension ) , hematologic , renal , atopic , alimentary psychiatric disorder , panic attack , diabetes , drug alcohol abuse Prior abdominal surgery uncomplicated appendectomy hernia repair Requiring medication might alter gut function , include anticholinergic , calcium channel blocker , beta blocker , laxative , prokinetics , protonpump inhibitor , nonsteroidal antiinflammatory drug Presence metallic implant , device metallic foreign body Pregnancy lactation ( female participant child bear age receive pregnancy test prior study ) Claustrophobia Regular smoking consumption alcohol drug Uncertainty willingness ability participant comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MRI , fat fraction , stomach , lipid emulsion</keyword>
</DOC>